Terms: = Sarcomas AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234 AND Clinical Outcome
4 results:
1. REGISTRI: Regorafenib in first-line of KIT/pdgfra wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Martin-Broto J; Valverde C; Hindi N; Vincenzi B; Martinez-Trufero J; Grignani G; Italiano A; Lavernia J; Vallejo A; Tos PD; Le Loarer F; Gonzalez-Campora R; Ramos R; Hernández-Jover D; Gutierrez A; Serrano C; Monteagudo M; Letón R; Robledo M; Moura DS; Martin-Ruiz M; López-Guerrero JA; Cruz J; Fernandez-Serra A; Blay JY; Fumagalli E; Martinez-Marin V
Mol Cancer; 2023 Aug; 22(1):127. PubMed ID: 37559050
[TBL] [Abstract] [Full Text] [Related]
2. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.
Hemming ML; Lawlor MA; Zeid R; Lesluyes T; Fletcher JA; Raut CP; Sicinska ET; Chibon F; Armstrong SA; Demetri GD; Bradner JE
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5746-E5755. PubMed ID: 29866822
[TBL] [Abstract] [Full Text] [Related]
3. A case of nonleukemic myeloid sarcoma with FIP1L1-pdgfra rearrangement: an unusual presentation of a rare disease.
Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
[TBL] [Abstract] [Full Text] [Related]
4. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.
Lagarde P; Pérot G; Kauffmann A; Brulard C; Dapremont V; Hostein I; Neuville A; Wozniak A; Sciot R; Schöffski P; Aurias A; Coindre JM; Debiec-Rychter M; Chibon F
Clin Cancer Res; 2012 Feb; 18(3):826-38. PubMed ID: 22167411
[TBL] [Abstract] [Full Text] [Related]
